

Contents

A Personal Foreword *xiii*

Preface *xv*

1	Basics of Targeted Drug Delivery	1
	<i>Kshama A. Doshi</i>	
1.1	Introduction	1
1.1.1	Concept of Bioavailability and Therapeutic Index	2
1.2	Targeted Drug Delivery	2
1.3	Strategies for Drug Targeting	3
1.3.1	Passive Targeting	4
1.3.1.1	Reticuloendothelial System (RES) System	4
1.3.1.2	Enhanced Permeability and Retention (EPR) Effect	4
1.3.1.3	Localized Delivery	4
1.3.2	Active Targeting	5
1.3.3	Physical Targeting	5
1.3.3.1	Ultrasound for Targeting	6
1.3.3.2	Magnetic Field for Targeting	6
1.4	Therapeutic Applications of Targeted Drug Delivery	6
1.4.1	Diabetes Management	6
1.4.2	Neurological Diseases	7
1.4.3	Cardiovascular Diseases	8
1.4.4	Respiratory Diseases	9
1.4.5	Cancer Indications	9
1.5	Targeted Drug-Delivery Products	10
1.6	Challenges	11
1.6.1	Passive Targeting and EPR Effect	12
1.6.2	Active Targeting	12
1.7	Scale-up and Challenges	13
1.8	Current Status	14
1.9	Conclusion and Prospects	15
	References	16

2	Addressing Unmet Medical Needs Using Targeted Drug-Delivery Systems: Emphasis on Nanomedicine-Based Applications	21
	<i>Chandrakantsing Pardeshi, Raju Sonawane, and Yogeshwar Bachhav</i>	
2.1	Introduction	21
2.2	Targeted Drug-Delivery Systems for Unmet Medical Needs	23
2.2.1	Targeting Ligands	25
2.2.1.1	Small Molecules as Targeting Ligands	25
2.2.1.2	Aptamers as Targeting Ligands	27
2.2.1.3	Antibodies as Targeting Ligands	28
2.2.1.4	Lectins as Targeting Ligands	28
2.2.1.5	Lactoferrins as Targeting Ligands	29
2.2.2	Targeting Approaches	29
2.2.2.1	Disease-Based Targeting	29
2.2.2.2	Location-Based Targeting	32
2.3	Regulatory Aspects and Clinical Perspectives	35
2.4	Conclusion and Future Outlook	38
	List of Abbreviations	38
	References	39
3	Nanocarriers-Based Targeted Drug Delivery Systems: Small and Macromolecules	45
	<i>Preshita Desai</i>	
3.1	Nanocarriers (Nanomedicine) – Overview and Role in Targeted Drug Delivery	45
3.2	Passive Targeting Approaches	50
3.2.1	Enhanced Permeability and Retention-Effect-Based Targeting	50
3.3	Active Targeting Approaches	52
3.4	Stimuli Responsive Targeted NCs	54
3.4.1	Redox Stimuli Responsive Targeted NCs	55
3.4.2	pH Stimuli Responsive Targeted NCs	56
3.4.3	Enzyme Stimuli Responsive Targeted NCs	57
3.4.4	Temperature Stimuli Responsive Targeted NCs	58
3.4.5	Ultrasound Stimuli Responsive Targeted NCs	59
3.4.6	Magnetic Field Stimuli Responsive Targeted NCs	59
3.5	Conclusion and Future Prospects	60
	References	60
4	Liposomes as Targeted Drug-Delivery Systems	69
	<i>Raghavendra C. Mundargi, Neetika Taneja, Jayeshkumar J. Hadia, and Ajay J. Khopade</i>	
4.1	Introduction	69
4.2	Liposome Commercial Landscape	72
4.3	Important Considerations in Development and Characterization of Liposomes	80

4.3.1	Selection of Lipids	80
4.3.2	Drug : Lipid Ratio	81
4.3.3	PEGylation	82
4.3.4	Ligand Anchoring	83
4.3.5	Drug-Loading Techniques	84
4.3.6	Physicochemical Characterization	85
4.3.7	Manufacturing Process	86
4.3.8	Product Stability	87
4.4	Targeted Delivery of Liposomes	88
4.4.1	Passive Targeting	89
4.4.2	Active-Targeted Delivery	92
4.4.2.1	Cancer Cell Targeting	94
4.4.2.2	Tumor Endothelium Targeting	98
4.5	Recent Clinical Trials with Liposomes with Investigational Liposome Candidates	102
4.6	Factors Influencing the Clinical Translation of Liposomes for Targeted Delivery	103
4.7	Conclusions and Future of Prospects of Targeted Liposomal-Delivery Systems	108
	List of Abbreviations	110
	References	112

5 Antibody–Drug Conjugates: Development and Applications 127

Rajesh Pradhan, Meghna Pandey, Siddhanth Hejmady, Rajeev Taliyan, Gautam Singhvi, Sunil K. Dubey, and Sachin Dubey

5.1	Introduction	127
5.2	Design of ADCs	128
5.2.1	Antibody	129
5.2.2	Linker	130
5.2.3	Payload	132
5.3	Mechanism of Action	133
5.4	Pharmacokinetic Considerations for ADCs	134
5.4.1	Heterogeneity of ADCs	134
5.4.2	Bioanalytical Considerations for ADCs	135
5.4.3	Pharmacokinetic Parameters of ADCs	136
5.4.3.1	Absorption	136
5.4.3.2	Distribution	136
5.4.3.3	Metabolism and Elimination	136
5.5	Applications of ADCs	137
5.5.1	Approved ADCs in the Market	137
5.5.1.1	Gemtuzumab Ozogamicin	137
5.5.1.2	Brentuximab Vedotin	139
5.5.1.3	Ado-Trastuzumab Emtansine (T-DM1)	139
5.5.1.4	Inotuzumab Ozogamicin	139

5.5.1.5	Polatuzumab Vedotin-piiq	140
5.5.1.6	Enfortumab Vedotin	140
5.5.1.7	Trastuzumab Deruxtecan	140
5.5.2	Use of ADCs in Rheumatoid Arthritis	141
5.5.3	Use of ADCs in Bacterial Infections	141
5.5.4	Use of ADCs in Ophthalmology	141
5.6	Resistance of ADC	142
5.7	Regulatory Aspects for ADCs	143
5.7.1	Role of ONDQA	143
5.7.2	Role of OBP	144
5.8	Conclusion and Future Direction	144
	References	145
6	Gene-Directed Enzyme–Prodrug Therapy (GDEPT) as a Suicide Gene Therapy Modality for Cancer Treatment	155
	<i>Prashant S. Kharkar and Atul L. Jadhav</i>	
6.1	Introduction	155
6.2	GDEPT for Difficult-to-Treat Cancers	159
6.2.1	High-Grade Gliomas (HGGs)	159
6.2.2	Triple-Negative Breast Cancer (TNBC)	161
6.2.3	Other Cancers	162
6.3	Novel Enzymes for GDEPT	164
6.4	Conclusions	165
	References	165
7	Targeted Prodrugs in Oral Drug Delivery	169
	<i>Milica Markovic, Shimon Ben-Shabat, and Arik Dahan</i>	
7.1	Introduction	169
7.1.1	Classic vs. Modern Prodrug Approach	170
7.2	Modern, Targeted Prodrug Approach	171
7.2.1	Prodrug Approach-Targeting Enzymes	171
7.2.1.1	Valacyclovirase-Mediated Prodrug Activation	172
7.2.1.2	Phospholipase A ₂ -Mediated Prodrug Activation	173
7.2.1.3	Antibody, Gene, and Virus-Directed Enzyme–Prodrug Therapy	175
7.2.2	Prodrug Approach Targeting Transporters	176
7.2.2.1	Peptide Transporter 1	177
7.2.2.2	Monocarboxylate Transporter Type 1	179
7.2.2.3	Bile Acid Transporters	180
7.3	Computational Approaches in Targeted Prodrug Design	181
7.4	Discussion	182
7.5	Future Prospects and Clinical Applications	183
7.6	Conclusion	183
	References	184

8	Exosomes for Drug Delivery Applications in Cancer and Cardiac Indications	193
	<i>Anjali Pandya, Sreeranjini Pulakkat, and Vandana Patravale</i>	
8.1	Extracellular Vesicles: An Overview	193
8.1.1	Evolution of Exosomes	194
8.1.2	Exosomes as Delivery Vehicles for Therapeutics	195
8.1.2.1	Endogenous Loading Methods	198
8.1.2.2	Exogenous Loading Methods	198
8.2	Exosomes as Cancer Therapeutics	199
8.2.1	Influence of Donor Cells	202
8.2.2	Different Therapeutic Cargo Explored in Cancer Therapy	202
8.2.2.1	Delivery of Proteins and Peptides	203
8.2.2.2	Delivery of Chemotherapeutic Cargo	204
8.2.2.3	Delivery of RNA	204
8.3	Exosome Based Drug Delivery for Cardiovascular Diseases	206
8.3.1	Delivery of Cardioprotective RNAs	207
8.3.2	Exosomes Modified with Cardiac Targeting Peptides	208
8.4	Clinical Evaluations and Future Aspects	210
8.5	Conclusion	211
	Acknowledgments	212
	References	212
9	Delivery of Nucleic Acids, Such as siRNA and mRNA, Using Complex Formulations	221
	<i>Ananya Pattnaik, Swarnaparabha Pany, A. S. Sanket, Sudiptee Das, Sanghamitra Pati, and Sangram K. Samal</i>	
9.1	Introduction	221
9.2	NA-Based Complex Delivery System	228
9.2.1	Classical NA-Based Complex Delivery System	229
9.2.1.1	Polymer-Based NA-Complex Delivery System	229
9.2.1.2	Lipid-Based Complex NA Delivery System	230
9.2.1.3	Peptide-Based Complex NA Delivery System	231
9.2.2	Advanced NA-Based Complex Delivery Systems	232
9.2.2.1	Inorganic and Hybrid NPs	232
9.2.2.2	Self-Assembled NA Nanostructures	233
9.2.2.3	Exosomes and NanoCells	233
9.3	Applications of NA-Complex Delivery Systems	234
9.3.1	Genome Editing	235
9.3.2	Cancer Therapy	237
9.3.3	Protein Therapy	238
9.4	Future Prospective	239
9.5	Conclusion	240
	Acknowledgments	240
	References	240

10	Application of PROTAC Technology in Drug Development	247
	<i>Prashant S. Kharkar and Atul L. Jadhav</i>	
10.1	Introduction	247
10.2	Design of PROTACS: A Brief Overview	252
10.3	Therapeutic Applications of PROTACS	254
10.3.1	Cancer	255
10.3.2	Neurodegenerative Disorders	261
10.3.3	Immunological Diseases	263
10.3.4	Viral Infections	264
10.4	Challenges and Limitations in the Development PROTACS	265
10.5	Future Perspectives	266
	References	266
11	Metal Complexes as the Means or the End of Targeted Delivery for Unmet Needs	271
	<i>Trevor W. Hambley</i>	
11.1	Introduction	271
11.2	Class 1: Chaperones	272
11.2.1	Chaperones that Protect Drugs	273
11.2.2	Delivery to the Cells or Environments to Be Targeted	275
11.2.3	Release from the Metal Where and When Required	276
11.3	Class 2: Active Metal Complexes	276
11.3.1	Targeted Platinum Agents	277
11.4	Class 3: Dual-Threat Metal Complexes	279
11.5	Targeting Strategies: The Chemical and Physical Environment	280
11.5.1	Hypoxia	281
11.5.2	pH-Based Targeting	282
11.5.3	The EPR Effect	283
11.6	Targeting Strategies: Transporters	284
11.7	Targeting Strategies: Enzyme Activation	286
11.8	Other Targeting Strategies	287
11.9	Conclusions	288
	References	289
12	Formulation of Peptides for Targeted Delivery	299
	<i>Pankti Ganatra, Karen Saiswani, Nikita Nair, Avinash Gunjal, Ratnesh Jain, and Prajakta Dandekar</i>	
12.1	Introduction	299
12.2	Peptides Used in Cancer Therapy	302
12.2.1	Lung Cancer	303
12.2.2	Melanoma	304
12.2.3	Pancreatic Cancer	306
12.2.4	Brain Cancer	307
12.2.5	Breast Cancer	309
12.2.6	Leukemia	312
12.3	Peptide-Targeting Based on Site of Action	315

12.3.1	Topical Delivery of Peptides	315
12.3.2	Ocular Delivery of Peptides	317
12.3.3	Brain Delivery of Peptides	319
12.3.4	Lung-Targeted Delivery of Peptides	321
12.4	Conclusion and Future Prospects	323
	References	324
13	Antibody-Based Targeted T-Cell Therapies	327
	<i>Manoj Bansode, Kaushik Deb, and Sarmistha Deb</i>	
13.1	Introduction	327
13.2	Immune-Directed Cancer Cell Death	328
13.3	Immunotherapy Strategies in Cancer	328
13.4	T-Cell Therapy	329
13.5	Naturally Occurring T Cells	329
13.6	Genetically Modified Occurring T Cells	330
13.7	Clinical Implication of T-Cell and CAR-T-Cell Therapy:	330
13.8	Antibody-Induced T-Cell Therapy	332
13.9	A Bispecific Antibody (BsAbs)-Induced T-Cell Therapy	332
13.10	Formats of BsAbs	335
13.11	Triomab Antibodies in T-Cell Therapy	335
13.12	Bispecific Antibodies in T-Cell Therapy	336
13.13	Clinically Approved T-Cell-Activating Antibodies	337
13.14	Prospects	337
13.15	Conclusion	339
	References	339
14	Devices for Active Targeted Delivery: A Way to Control the Rate and Extent of Drug Administration	349
	<i>Jonathan Faro Barros, Phedra F. Sahraoui, Yogeshvar N. Kalia, and Maria Lapteva</i>	
14.1	Introduction	349
14.2	Macrofabricated Devices – Drug Infusion Pumps	351
14.2.1	Peristaltic Pumps	351
14.2.2	Gas-Driven Pumps	352
14.2.3	Osmotic Pumps	353
14.2.4	Insulin Pumps	354
14.2.4.1	Diabetes and Insulin Product Development	354
14.2.4.2	Open-Loop Insulin Delivery Systems	355
14.2.4.3	Closed-Loop Insulin Delivery Systems	360
14.3	Microfabricated and Nanofabricated Drug Delivery Devices	364
14.3.1	Microelectromechanical Systems (MEMS)	364
14.3.1.1	Microchip-Based MEMS	364
14.3.1.2	Pump-Based MEMS	366
14.3.1.3	MEMS – Efforts to Close the Loop	368
14.3.2	Nanofabricated Drug Delivery Devices	369

14.4	Noninvasive Active Drug Delivery Systems: Iontophoresis	372
14.5	Conclusions	376
	Acknowledgments	377
	List of Abbreviations	377
	References	378

15 Drug Delivery to the Brain: Targeting Technologies to Deliver Therapeutics to Brain Lesions 389

Nishit Pathak, Sunil K. Vimal, Cao Hongyi, and Sanjib Bhattacharyya

15.1	Introduction	389
15.2	Brain Tumor	390
15.2.1	Obstacles to Brain Tumor-Targeted Delivery	391
15.2.2	Brain-Tumor-Focused Nano-Drug Delivery	393
15.3	Neurodegenerative Diseases	396
15.3.1	Alzheimer's Disease (AD)	396
15.3.1.1	Alzheimer's Disease Focused on Drug Delivery	396
15.3.2	Parkinson's Disease	399
15.3.2.1	Drug Delivery Focussed on Parkinson's Drug Disease	399
15.3.3	Cerebrovascular Disease	400
15.3.3.1	Drug Delivery for Cerebrovascular Disease	400
15.3.4	Inflammatory Diseases (ID)	402
15.3.4.1	Inflammatory Diseases (ID) Focused on Drug Delivery	402
15.3.4.2	Drug Delivery for the Treatment of Neuro-AIDS	403
15.3.5	Drug Delivery for Multiple Sclerosis (MS)	403
15.4	Drug Delivery for CNS Disorders	404
15.4.1	Tau Therapy	405
15.4.2	Immunotherapy	407
15.4.3	Gene Immunotherapy (GIT)	407
15.4.4	Chemotherapy (CT)	408
15.4.5	Photoimmunotherapy (PIT)	408
15.5	Future Prospects	410
15.6	Conclusions	410
	List of Abbreviations	411
	References	412

Index 425